Aligos Therapeutics Inc (ALGS)
19.46
+0.01
(+0.05%)
USD |
NASDAQ |
Nov 14, 16:00
19.40
-0.06
(-0.31%)
After-Hours: 20:00
Aligos Therapeutics Revenue (Quarterly): 1.269M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.269M |
| June 30, 2024 | 1.061M |
| March 31, 2024 | 0.986M |
| December 31, 2023 | 2.681M |
| September 30, 2023 | 3.239M |
| June 30, 2023 | 6.886M |
| March 31, 2023 | 2.723M |
| December 31, 2022 | 3.537M |
| Date | Value |
|---|---|
| September 30, 2022 | 4.106M |
| June 30, 2022 | 3.693M |
| March 31, 2022 | 2.571M |
| December 31, 2021 | 0.367M |
| September 30, 2021 | 1.537M |
| June 30, 2021 | 1.545M |
| March 31, 2021 | 0.91M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.367M
Minimum
Dec 2021
6.886M
Maximum
Jun 2023
2.474M
Average
2.571M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Haemonetics Corp | 345.51M |
| Pliant Therapeutics Inc | -- |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.05M |
| IGC Pharma Inc | 0.272M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.26M |
| Total Expenses (Quarterly) | 21.40M |
| EPS Diluted (Quarterly) | -3.07 |
| Enterprise Value | -5.137M |
| Profit Margin (Quarterly) | -1.52K% |
| Earnings Yield | -87.90% |
| Normalized Earnings Yield | -87.90 |